Mere end 80% af de tidligere behandlede patienter kan forvente at få bivirkninger; de bivirkninger, der er indberettet mest almindeligt, forekommer sædvanligvis i den første behandlingsuge.
More than 80% of previously treated patients may be expected to experience adverse reactions; the most commonly reported reactions usually occur during the first week of therapy.